Synapse - Vicky Makker

Results (267)

SIENDO/ENGOT-EN5: A randomized phase III trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer

Meeting Abstract

Vergote, I.; Hamilton, E. P.; Romero, I.; Guerra, E. M.; Buscema, J.; Laenen, A.; Perri, T.; Estevez-Garcia, P.; Raposo, C. G.; Levy, T.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer

Meeting Abstract

Marth, C.; Vulsteke, C.; Perez, M. J. R.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR plus ) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC)

Meeting Abstract

Grisham, R. N.; Li, K.; Iasonos, A.; Girshman, J.; Cadoo, K. A.; Kyi, C.; Makker, V.; Cohen, S. M.; O'Cearbhaill, R. E.; Sabbatini, P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

ENGOT-en9/LEAP-001: A phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer

Meeting Abstract

Randall, L.; Marth, C.; Vulsteke, C.; Jesús Rubio, M.; Makker, V.; Braicu, I.; McNeish, I.; Madry, R.; Ayhan, A.; Hasegawa, K.; more...
International Journal of Gynecological Cancer (2020)

Fulltext@MSK | Save

Distant metastatic spread and clonal evolution of high-grade endometrial cancers

Meeting Abstract

Miller, K.; Selenica, P.; Reis-Filho, J.; Abu-Rustum, N. R.; Makker, V.; Aghajanian, C. A.; Iacobuzio-Donahue, C. A.; Murali, R.; Weigelt, B.
International Journal of Gynecological Cancer (2020)

Fulltext@MSK | Save

Impact of adjuvant therapy on oncologic outcomes in early-stage uterine clear cell carcinoma

Meeting Abstract

Pedra Nobre, S.; Ataseven, B.; du Bois, A.; Makker, V.; Alektiar, K.; Leitao, M. M. Jr; Abu-Rustum, N. R.; Mueller, J. J.
Gynecologic Oncology (2020)

Fulltext@MSK | Save

ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer

Meeting Abstract

Marth, C.; Vulsteke, C.; Rubio, M. J. R.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; more...
Gynecologic Oncology (2020)

Fulltext@MSK | Save

Characterization and management of adverse reactions in patients with endometrial carcinoma receiving lenvatinib plus pembrolizumab (Study 111/KEYNOTE-146): Nurse roles in patient education and adverse-reaction management

Meeting Abstract

Soldan, K.; Johns, C.; Taylor, M. H.; Gillis, K.; Orlowski, R.; Min, R.; Makker, V.
Journal of Oncology Navigation & Survivorship (2020)

Fulltext@MSK | Save

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

Journal Article

Voss, M. H.; Gordon, M. S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D. C.; Cervantes, A.; Puzanov, I.; Pili, R.; more...
British Journal of Cancer (2020)

Fulltext@MSK | Save

Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer

Meeting Abstract

Rubinstein, M. M.; Hyman, D.; Caird, I.; O'Cearbhaill, R.; Grisham, R.; Tew, W.; Hensley, M.; Sabbatini, P.; Aghajanian, C.; Iasonos, A.; more...
Molecular Cancer Research (2020)

Fulltext@MSK | Save